anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Diabetes mellitus is generally accompanied by dyslipidaemia, but inconsistent relationships between lipid profiles and diabetes are noted. Moreover, genetic variations in insertion/deletion (I/D) polymorphisms at angiotensin-converting enzyme gene (ACE) and T/C polymorphisms in the angiotensin type 1 receptor gene (AGTR1) are related to diabetes and lipid levels, but the associations are controversial. Thus, the current research aimed to explore the effects of ACE I/D, AGTR1 rs5182 and diabetes mellitus on serum lipid profiles in 385 Chinese participants with an average age of 75.01 years.
METHODS: The ACE I/D variant was identified using the polymerase chain reaction (PCR) method, whereas the AGTR1 rs5182 polymorphism was identified using the PCR-based restriction fragment length polymorphism (PCR-RFLP) method and verified with DNA sequencing. Total cholesterol (TC), triglyceride (TG), apolipoprotein A (ApoA), apolipoprotein B (ApoB), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were measured using routine methods, and the lipid ratios were calculated.
RESULTS: ACE I/D, but not AGTR1 rs5182, was a predictor of TG/HDL-C for the whole study population. Both ACE I/D and AGTR1 rs5182 were predictors of HDL-C and LDL-C levels in females but not in males. Moreover, in females, diabetes mellitus and ACE I/D were identified as predictors of TG and TG/HDL-C, whereas AGTR1 rs5182 and diabetes mellitus were predictors of TG/HDL-C. Moreover, diabetes mellitus and the combination of ACE I/D and AGTR1 rs5182 variations were predictors of TG and TG/HDL-C exclusively in females.
CONCLUSIONS: The results demonstrated the potential for gender-dependent interactions of ACE I/D, AGTR1 rs5182, and diabetes on lipid profiles. These findings may serve as an additional explanation for the inconsistent changes of blood lipids in individuals with diabetes mellitus, thereby offering a novel perspective for the clinical management of blood lipid levels in diabetic patients.
PURPOSE:An aerosol composition, containing a physiologicaly active substance immobilized in a structure, e.g. a fiber aggregate or sponge, of a high polymer as an active constituent, and scarcely deteriorating the activity by aerosolization and during preservation. CONSTITUTION:An aerosol composition containing an immobilized material of a physiologically active substance, e.g. an enzyme, hormone, antibiotic or anticancer agent, in a structure, e.g. a fiber aggregate, sponge, powder or film made from a high polymer as a material, as an active constituent. A biologically absorbable gelatin, chitin collagen, oxidized cellulose, etc. may be preferred for the material the physiologically active substance is immobilized by bonding, adsorbing or entrapping the substance in the above-mentioned structure. Thus, the deterioration in activity is less than that of the physiologically active substance used as the active constituent in the aerosol composition without immobilization, and the composition can be accurately and easily used regardless of application sites.
The Presence of lymph node metastases in cancer is a key factor for determining prognosis and forming an adequate treatment plan. Determining lymph node status, however, is a challenge. Ferumoxtran-10, an ultrasmall superparamagnetic iron oxide (USPIO) particle has proven to be a valuable contrast agent for detecting lymph node metastases using magnetic resonance imaging (MRI) in various types of cancer (also called nano-MRI). For small lymph node metastases (\<5mm) the diagnostic accuracy of this technique does, however, drop substantially. Most of the studies that have been performed with these particles used a 1.5 Tesla or 3 Tesla MRI scanner. The investigators would like to increase the resolution of nano-MRI by using a 7 Tesla scanner, such that the investigators can increase the sensitivity of this technique for small lymph nodes. With this study the investigators would like to validate the results of this technique with pathology in rectal and breast cancer. In these cancer types many patients undergo a surgical lymph node dissection by bulk excision of tissue including the nodes, enabling a node-to-node comparison between MRI and pathology to validate our nano-MRI results . If successful this technique would form a non-invasive alternative to the current lymph node staging techniques such as surgery. Additionally (if metastatic nodes are present), it could complement image guided focal therapies on lymph node metastases such as radiotherapy.
PURPOSE:To enable the optimum allocation and management by connecting medical treatment units such as clinic section, wards, or the like as medical treatment subsystems to organize a medical service network. CONSTITUTION:Medical treatment units such as clinic sections, wards, or the like are regarded as medical treatment subsystems 3-6 and are connected using networks 10 and 100. Further, medical information is executed by a host 1 and data base 2, the management of medical information is centralized, and in data base 2 various types of mask information, the situation and condition of each subsystem 3-6 and medical charts are also centrally managed. Furthermore, overall preserved chart information (inactive charts themselves and related information) for the entire hospital are also unitarily and centrally managed. Moreover, clinic section subsystems 4 and 5 basically function autonomously, active charts regarding a relevant clinic section are maintained in an internal preservation chart file to distributively manage charts. Accordingly, various types of information can be allocated and managed in conformity with the natures of the generating source, utilizing method, user, and management system, etc.
This study aims to uncover the heterogeneity of endothelial cells (ECs) in colorectal cancer (CRC) and their crucial role in angiogenesis, with a special focus on tip cells. Using single-cell RNA sequencing to profile ECs, our data suggests that CRC ECs predominantly exhibit enhanced angiogenesis and decreased antigen presentation, a shift in phenotype largely steered by tip cells. We also observed that an increase in the density and proportion of tip cells correlates with CRC occurrence, progression, and poorer patient prognosis. Furthermore, we identified endothelial cell-specific molecule 1 (ESM1), specifically expressed in tip cells, sustains a VEGFA-KDR-ESM1 positive feedback loop, promoting angiogenesis and CRC proliferation and migration. We also found the enrichment of KDR in tip cells and spotlight a unique long-tail effect in VEGFA expression: while VEGFA is primarily expressed by epithelial cells, the highest level of VEGFA expression is found in individual myeloid cells. Moreover, we observed that effective PD-1 blockade immunotherapy significantly reduced tip cells, disrupting the VEGFA-KDR-ESM1 positive feedback loop in the process. Our investigation into the heterogeneity of ECs in CRC at a single-cell level offers important insights that may contribute to the development of more effective immunotherapies targeting tip cells in CRC.
Cohorts IV-VI: Patients receive 1 of 3 doses of oral lycopene twice daily and a multivitamin once daily. Treatment in all arms continues for 4-6 weeks, until prostatectomy.
INTRODUCTION: Endovascular treatment (ET) is a beneficial treatment for M1-2 occlusions of the middle cerebral artery. Mortality and disability rates are high if large vessel occlusions are not treated. While these rates are lower in M3 occlusions, important branch blockages can lead to disability. Endovascular treatment of small vessel occlusions is difficult, and there are no studies on the effectiveness of endovascular treatment for M3 occlusions. Accordingly, in this study, our aim was to assess the feasibility, safety, and preliminary efficacy of endovascular therapy for M3 occlusions.
METHODS: This study involved a retrospective analysis of a prospectively collected from two centres for acute ischemic stroke of the anterior system between July 2015 and April 2020. Demographic, radiologic, procedural and outcome variables were collected for patients who underwent endovascular therapy for acute ischemic stroke of the anterior system.
RESULTS: Complete or near complete reperfusion (mTICI 2b-3) of the M3 occlusion was achieved in 15 cases (38.5%). Complete (mTICI 3) reperfusion was achieved in 24 cases (61.5%). Twenty-six patients were treated for primary M3 occlusion, while 13 patients with M3 occlusion were treated as a rescue strategy after successful treatment of a proximal greater vascular occlusion. Complete or near complete reperfusion (mTICI 2b-3) of primary occlusion was achieved in eight cases (30.8%), and complete (mTICI 3) reperfusion was achieved in 18 cases (69.2%). In addition, complete or near complete reperfusion (mTICI 2b-3) of rescue M3 occlusion was achieved in seven cases (%53.8), while complete (mTICI 3) reperfusion was achieved in six cases (46.2%). Only one patient with primary M3 occlusion had ICH due to extravasation. The patient's neurological examination one month later was normal.
CONCLUSIONS: This retrospective study demonstrates that endovascular treatment of M3 occlusions is safe, effective and reliable.
Patients randomized to DEB TACE/SBRT arm will undergo DEB-TACE as in standard arm. SBRT will be initiated 4-6 weeks after last TACE procedure. During this period patients will stop Sorafenib. SBRT once initiated will continue for 2-2.5 weeks. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier, or in patients who fail to tolerate it after dose modifications. QOL will be evaluated at baseline, before each cycle of TACE, 1 month after SBRT and three monthly thereafter. Hepatobiliary CTCAE will be completed at baseline, after each TACE, before SBRT and after completion of SBRT and subsequently at each follow up.
Provided are a Bifidobacterium animalis subsp. lactis i797, a method for the separation and purification thereof, and a use thereof. The strain was is deposited in the China General Microbiological Culture Collection Center on Aug. 20, 2019, wherein the deposit address is Building 3, No. 1 Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC NO. 18403. The Bifidobacterium animalis subsp. lactis i797 can adjust the balance of intestinal flora, improve stool characteristics, and has a better survival rate in simulated digestive juice; in addition, after being stored at 37° C., a relatively high temperature which is suitable for the growth of lactic acid bacteria, same can successfully control post-acidification.
Copolymers of formula (I) wherein the bonds between the glucoside units are .beta. (1$m(8)4), the degree of polymerization referred to a single glucoside unit varies from about 50 to 50,000, R is a free or esterified carboxy group and S is an amino or acylamino group. The part designated by x may vary between about 5 % and 100 % and that designated by y may vary between about 95 % and 0 %. At least a part of the R groups are esterified carboxy groups, and at least a part of the S groups are acylamino groups. Salts of these copolymers are also disclosed. The products of the invention are particularly useful in the cosmetic field.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention refers to pharmacology, particularly to a composition with antineoplastic and adaptogenic activity. The composition with antineoplastic and adaptogenic activity containing: reishi mushroom bracket, raw roots of common licorice or Ural licorice, fennel seeds, refined Altai mumijo, yellow melilot herb. The composition with antineoplastic and adaptogenic activity containing: reishi mushroom bracket, raw roots of common licorice or Ural licorice, fennel seeds, refined Altai mumijo, yellow melilot herb, shelf fungus, common valerian roots, common nettle leaves, motherwort herb, aerial wormwood, spiny eleutherococcus roots. The composition with antineoplastic and adaptogenic activity containing: reishi mushroom bracket, raw roots of common licorice or Ural licorice, fennel seeds, refined Altai mumijo, yellow melilot herb, kidney bean valves, common St. John's wort herb, fibre flax seeds, hop cones, common nettle leaves, whortleberry leaves, aerial wormwood. A drug with antineoplastic and adaptogenic activity (vesions). ^ EFFECT: composition improves tolerance to etiotropic therapy in oncological patients. ^ 21 cl, 9 ex
Supplementation of placebo with sunflower fatty at doses of 2.7 g/d were provided in 10 capsules per day (4 in the morning, 3 in the afternoon and 3 at night) during a period of 6 months. The capsules sizes are specially for children to improved the feeding process. This placebo is sunflower oil, so, it did not present anti-inflammatory or insulin sensitivity effects.
A bone mixture for application to incisions to enhance clotting and for use as a bed or filler between bone sections in general surgery and dentistry consists of pulverized viable non-human animal bone and a plasma clot as a binder for the said pulverized bone, the plasma clot substance, e.g. blood plasma, being obtained from the same species of animal, but not necessarily the same animal, as that from which the bone is obtained.  Bone is preserved according to the method of Specification 827,746 by removing bone from a healthy, non-human animal body under sterile conditions and placing the removed bone in a container having therein an antibiotic such as penicillin or a sulpha drug such as sulphadiazine, and blood plasma or blood serum from the same species of animal from which the bone was removed.  Bones may be from domestic animals, e.g. sheep, bovine, hogs, dogs, cats and horses.  The bone so preserved is divided into small pieces, by e.g. sawing, and is then pulverized without cauterization in a grinder or mixer, and is then mixed with the plasma clot substance under sterile conditions at about 40 DEG  F. In the presence of the bone, the blood plasma forms a clot, the calcium from the bone reacting with the prothrombin and thromoplastin from the blood plasma to form thrombin which in turn reacts with the fibrinogen of the blood plasma to form fibrin.  A suitable gel is formed with 10 parts of bone and 1 part of plasma clot.  If not used immediately, it must be maintained under sterile conditions at 40-50 DEG  F.  Preferably the mixture is enclosed in an osmotic membrane immersed in blood plasma.
Knee osteoarthritis (OA) is a highly prevalent, leading cause of pain that limits physical functioning in older adults. Although clinical practice guidelines recommend physical exercise for managing symptoms of knee OA, several systematic reviews indicate that exercise intervention studies provide only short-term benefits (lasting 6 months) for knee OA. Many older adults with painful knee OA return to sedentary lifestyles when structured exercise programs end6. Efforts to increase and sustain physical activity in this population will require promoting self-regulatory skills to develop confidence to maintain an active lifestyle and manage symptoms that often limit activity. Therefore, we developed a group-based behavioral health (BH) program for older adults with painful knee OA that complements Enhance Fitness (EF) - a multicomponent, community-based exercise program for older adults, involving balance, strength, and endurance training. The Behavioral Health (BH) program will have 10, 1-hour weekly classes spread over 4 months, while the Health Education (HE) program will be equally matched for attention with classes on aging and health. In parallel with BH/HE programs, all study subjects will participate in Enhance Fitness (EF) exercise classes that will be held for 1-hour, 3 times a week for 4 months. EF+BH intervention (versus EF+HE) improves physical activity, pain, physical function, and other outcomes in older adults with knee OA.
The invention relates to a placenta immunity adjusting medicine capsule with each medical dose unit containing 1/50 to 1/10000mL placenta tissue fluid. A poultry egg serves as an attachment agent and is added with the placenta tissue fluid for full agitation. The solution is dried and then crushed into powder which is then put into capsules. The medicine capsule can stimulate the immunity action, thus achieving the aim of health care and curing and preventing diseases. As the amount of the effective ingredients is small, no adverse drug reaction is occurred. Seen through the treatment to prostatomegaly urinary retention, nephritis, epilepsy, inflammatory aches, Meniere disease, etc., the capsule achieves good result.
The present invention relates to a composition for preventing, alleviating or treating oral disease, including an extract of Chrysanthemum indicum as an active ingredient. The present invention provides a pharmaceutical composition for preventing or treating oral diseases, including an extract of Chrysanthemum indicum as an active ingredient. The present invention also provides an oral hygienic composition for preventing or alleviating oral diseases, including an extract of Chrysanthemum indicum as an active ingredient. The extract of Chrysanthemum indicum used according to the present invention shows an activity of inhibiting growth of strains causing oral diseases, and thus medicines including the extract of Chrysanthemum indicum as an active ingredient are effective for preventing and treating oral diseases, such as dental carries and periodontal disease. Particularly, when the natural extract according to the present invention is used for toothpaste, mouthwash, or the like, it is possible to inhibit growth and activity of oral pathogenic bacteria and to effectively prevent formation of dental plaque, which is a bacterial precipitate. In addition, since the natural extract according to the present invention uses a naturally occurring substance proven to be safe as an active ingredient, there is an advantage of having little side effects.
The first cohort will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml. The anatomical midline point of the muscle will be identified on the skin and two to six vector injections will be distributed in the direction of an X. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
A snap-fit locking mechanism assembly for a water filter cartridge cover in a household appliance includes a housing of the water filter cartridge cover being coupled to the household appliance. The housing can be positioned adjacent to a water filter cartridge within the household appliance. The water filter cartridge cover can include a cover panel positioned within the housing. The water filter cartridge cover can include an annular snap-fit lock that can rotate the cover panel between an open position and a closed position. The open position can provide access to the water filter cartridge. The water filter cartridge cover can include a cantilever snap-fit lock that can couple the cover panel to the housing in the closed position. A method for locking the cartridge cover and a household appliance are also provided.
The present invention relates to a medical composition which has functions of relief cough, dispersing of phlegm and relief of asthma for curing diseases of cough, cough with dyspnea, expectoration, etc. caused by acute and chronic bronchitis. The present invention aims to replenish the insufficiency of the existing oral medicine preparation for treating diseases of cough, cough with dyspnea, expectoration, etc. caused by acute and chronic bronchitis. The present invention provides a cough relief dripping pill which has the advantages of high biologic utilization rate, fast release of medicine, fast excellence, high medicine content, convenient administration, low cost and no pollution in a production process. The cough relief dripping pill of the present invention is formed by the preparation of the extract of the active ingredients of six kinds of traditional Chinese medicine of loquat leaf, poppy shell, stemona, ephedrae, platycodon root and menthol together with medicinal carriers which serve as base materials.
FOLFOX regimen include oxaliplatin and 5-Fu. Oxaliplatin has a moderate emetic potential and 5-Fu has a low emetic potential according to European guideline for the prevention of nausea and vomiting caused by chemotherapy and radiotherapy. The Guideline recommend that patients receiving moderately emetogenic chemotherapy receive a three-drug regimen of 5-HT3, dexamethasone, and NK1-RA (aprepitant, fosaprepitant, netupitant or rolapitant). However, HAIC treatment is not through peripheral or central venous infusion of chemotherapy drugs as in other cancers, but through hepatic artery infusion of chemotherapy drugs. Chemotherapy drugs are mainly concentrated in the liver and belong to local chemotherapy, rather than systemic chemotherapy through the venous system. Therefore, although the HAIC regimen includes oxaliplatin and 5-Fu, two chemotherapeutic drugs that may cause vomiting, the literature on whether three-drug regimen is also needed to prevent vomiting has been less publicly reported. In order to further determine whether three-drug regimen is necessary, this project intends to conduct a multi-center, randomized, controlled trial to evaluate the efficacy and safety of aprepitant combined with granisetron and dexamethasone versus granisetron and dexamethasone in preventing nausea and vomiting in HCC patients receiving HAIC treatment. The results of this project will provide a reference for improving the quality of life of HCC patients during HAIC treatment, the compliance of follow-up treatment and saving medical resources.
A process for preparing a . b. -lactam antibiotic dry powder formulation comprising adding sugar granules to a container at a first filling station and adding a premix containing a . b. -lactam antibiotic powder, sugar granules and dry excipients/additives to the sugar in the container at a second filling station. The amount of sugar filled to the container at the first station is preferably from 70 to 95 % by weight of the total sugar content of the dry powder formulation with the balance of the sugar being added in the premix at the second station. The amount of premix added at the second station may be substantially the same across a plurality of batches of the same or of different . b. -lactam antibiotics. Suitable . b. -lactam antibiotics include amoxycillin trihydrate and phenoxymethylpenicillin potassium.
We will test the feasibility of affordable robot therapy in three Aims. In Aim 1, we will optimize for the Botswana context, an affordable technology-based robot system with four exercise stations. We will optimize a prototype of our provisionally patented robot gym system, REHAB CARES, for therapy. Optimization will include increasing cost-effectiveness, utilizing more local resources and manufacturing, and using mobile health android platforms for games and data acquisition. In Aim 2, the efficiency of the newly modified robot system compared to standard of care will be assessed using 30 patients who have experienced a stroke, with or without HIV, will be recruited from those who are being treated by Princess Marina Hospital (PMH) and living in the surrounding community. They will receive therapy using the robot gym system and receive standard of care. We will assess functional outcomes including motor impairment, function, and quality of life. The study outcomes would then inform rehabilitation practices for PLHIV with stroke, with or without HIV, and suggest that affordable technology-mediated rehabilitation can reduce their motor dysfunction and resulting long-term disability.